<DOC>
	<DOCNO>NCT00157690</DOCNO>
	<brief_summary>The primary objective study determine efficacy 70 mg alendronate weekly compare placebo . This measure percent change lumbar spine ( LS ) bone mineral density ( BMD ) adult cystic fibrosis ( CF ) patient one year treatment . The investigator hypothesize adult CF patient osteopenia osteoporosis , alendronate 70 mg weekly produce mean increase baseline lumbar spine BMD great observe placebo 12 month .</brief_summary>
	<brief_title>Study Alendronate Prevent Treat Osteoporosis Cystic Fibrosis Patients</brief_title>
	<detailed_description>Randomized controled trial begin establish efficacy safety bisphosphonates CF patient decrease BMD . The development weekly dose regimen alendronate low prevalence esophageal adverse event may advantageous therapeutic option high-risk population . This one-year randomized , double-blind , placebo-controlled , multicentre study 55 CF patient osteopenia osteoporosis . Six Canadian centre participate study . Patients randomized treatment receive 70 mg oral alendronate weekly , control receive identical placebo weekly . All medication dispense conceal . There dose modification course trial . All patient receive total 1000 mg calcium , 500 supplementation 500 diet . All patient continue take vitamin D supplementation ( 2 tablet per day , 400 IU vitamin D/tablet ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>1 . CF ; confirm positive sweat test DNA analysis 2. age 18 year time inform consent 3. osteopenia ( 2.5 &lt; BMD tscore &lt; 1.0 ) osteoporosis ( BMD tscore &lt; 2.5 ) tscore LS ( 14 ) total hip 4. provision inform consent 1. endoscopyproven esophagitis , gastritis , ulceration , abnormality esophagus delay esophageal empty stricture , achalasia , esophageal varix 2. significantly impaired renal function ; define serum creatinine &gt; 177 umol/L 3. current recent ( within 1 year prior randomization ) consumption excess alcohol abuse drug ; excess alcohol define four follow per day , combination four follow per day : 30 mL distil spirit , 240 mL beer , 120 mL wine 4. history prior organ transplantation 5. condition may interfere evaluation LS BMD determine screen radiograph radiologist central facility e.g . spinal fusion , confluent aortic calcification , surgical artefact , excessive osteophyte , permanent artefact ; hip prostheses condition may interfere evaluation hip BMD 6. participation another clinical trial 30 day prior enrolment within 6 halflives study drug applicable 7. pregnancy , lactation , desire become pregnant ; safe effective birthcontrol must use 8. know hypersensitivity abnormal reaction study drug bisphosphonates 9. use drug know affect bone within 6 month start trial medication ( e.g . thiazide , diuretic , calcitonin , calcitriol , anabolic steroid , estrogen estrogenrelated drug ( e.g . tamoxifen , raloxifene , tibolone high dose vaginal estrogen ) , progesterone , fluoride : include birth control pill 10. patient currently receive another bisphosphonate treatment efficacy establish ; patient intolerant respond another bisphosphonate consider inclusion ; patient must cease treatment bisphosphonate least 1 year prior enrolment 11. use systemic corticosteroid dose least 7.5 mg/day great within last 6 month 12. concomitant use investigational drug study medication 13. current recent ( within 1 year prior randomization ) metabolic bone disorder secondary osteoporosis , Paget 's disease , renal osteodystrophy , osteomalacia ( 25OHD &lt; 25nmol/L ) , hypoparathyroidism , hyperparathyroidism ; TSH outside normal laboratory range , value assess clinically significant investigator ; replacement therapy , dose stable TSH within normal range minimum 6 week prior trial enrolment 14. hypocalcemia cause , correct low albumin 15. history cancer ; relatively benign skin malignancy , basal cell carcinoma squamous cell carcinoma patient history successfully treat cervical carcinoma istu , document sixmonth remission require study entry 16. poor medical psychiatric risk treatment investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Alendronate</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>